Try a new search

Format these results:

Searched for:



Total Results:


COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study

Yan, Di; Kolla, Avani M; Young, Trevor; Fried, Lauren; Shankar, Shruthi; Rangel, Lauren; Yin, Lu; Castillo, Rochelle; Steuer, Alexa; Svigos, Katerina; Izmirly, Peter; Sekar, Vaish; Lesser, Robert; Solomon, Gary; Blank, Rebecca B; Haberman, Rebecca H; Neimann, Andrea L; Scher, Jose U
PMID: 35373153
ISSN: 2666-3287
CID: 5219542

GRAPPA 2020 Research Award Recipients

Castillo, Rochelle L; Yan, Di; Ashhurst, Anneliese S; Elliott, Ashley; Angioni, Maria Maddalena; Scher, Jose U; Naik, Shruti; Neimann, Andrea; Byrne, Scott N; Payne, Richard J; FitzGerald, Oliver; Pennington, Stephen R; Cauli, Alberto; Chandran, Vinod
At the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting, a summary of the research conducted by the recipients of the 2020 GRAPPA Research Awards was presented by the awardees. The summary of the 4 presentations is provided here.
PMID: 35293338
ISSN: 0315-162x
CID: 5183902

A Randomized Open Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation

Garshick, Michael S; Drenkova, Kamelia; Barrett, Tessa J; Schlamp, Florencia; Fisher, Edward A; Katz, Stuart; Jelic, Sanja; Neimann, Andrea L; Scher, Jose U; Krueger, James; Berger, Jeffrey S
PMID: 34808233
ISSN: 1523-1747
CID: 5063372

Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease

Haberman, Rebecca H; Um, Seungha; Axelrad, Jordan E; Blank, Rebecca B; Uddin, Zakwan; Catron, Sydney; Neimann, Andrea L; Mulligan, Mark J; Herat, Ramin Sedaghat; Hong, Simon J; Chang, Shannon; Myrtaj, Arnold; Ghiasian, Ghoncheh; Izmirly, Peter M; Saxena, Amit; Solomon, Gary; Azar, Natalie; Samuels, Jonathan; Golden, Brian D; Rackoff, Paula; Adhikari, Samrachana; Hudesman, David P; Scher, Jose U
PMID: 35403000
ISSN: 2665-9913
CID: 5218902

CCL20 in Psoriasis: A Potential Biomarker of Disease Severity, Inflammation, and Impaired Vascular Health

Elnabawi, Youssef A; Garshick, Michael S; Tawil, Michael; Barrett, Tessa J; Fisher, Edward A; Lo Sicco, Kristen; Neimann, Andrea L; Scher, Jose U; Krueger, James; Berger, Jeffrey S
BACKGROUND:Psoriasis is associated with increased cardiovascular risk that is not captured by traditional pro-inflammatory biomarkers. OBJECTIVE:To investigate the relationship between psoriasis area and severity index (PASI), circulating pro-inflammatory biomarkers, and vascular health in psoriasis. METHODS:In psoriasis and age, sex-matched controls, 273 proteins were analyzed utilizing the OLINK platform, while vascular endothelial inflammation and health was measured via direct transcriptomic analysis of brachial vein endothelial cells. RESULTS:= 48.18, p<0.001) in predicting vascular endothelial inflammation. LIMITATIONS/CONCLUSIONS:Our study was observational and does not allow for causal inference in the relationship between CCL20 and cardiovascular risk. CONCLUSION/CONCLUSIONS:We demonstrate that CCL20 expression has a strong association with vascular endothelial inflammation, reflects systemic inflammation, and may serve as a potential biomarker of impaired vascular health in psoriasis.
PMID: 33259876
ISSN: 1097-6787
CID: 4694102

Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York [Letter]

Haberman, Rebecca; Axelrad, Jordan; Chen, Alan; Castillo, Rochelle; Yan, Di; Izmirly, Peter; Neimann, Andrea; Adhikari, Samrachana; Hudesman, David; Scher, Jose U
PMID: 32348641
ISSN: 1533-4406
CID: 4438562

IL-17 Inhibition in Spondyloarthritis Associates with Subclinical Gut Microbiome Perturbations and a Distinctive IL-25-Driven Intestinal Inflammation

Manasson, Julia; Wallach, David S; Guggino, Giuliana; Stapylton, Matthew; Badri, Michelle H; Solomon, Gary; Reddy, Soumya M; Coras, Roxana; Aksenov, Alexander A; Jones, Drew R; Girija, Parvathy V; Neimann, Andrea L; Heguy, Adriana; Segal, Leopoldo N; Dorrestein, Pieter C; Bonneau, Richard; Guma, Monica; Ciccia, Francesco; Ubeda, Carles; Clemente, Jose C; Scher, Jose U
OBJECTIVE:To characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome of psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients. METHODS:Fecal samples from PsA/SpA patients pre- and post-treatment with tumor necrosis factor inhibitors (TNFi; n=15) or an anti-interleukin (IL)-17A monoclonal antibody inhibitor (IL-17i; n=14) underwent sequencing (16S, ITS and shotgun metagenomics) and computational microbiome analysis. Fecal levels of fatty acid metabolites and cytokines/proteins implicated in PsA/SpA pathogenesis or intestinal inflammation were correlated with sequence data. Additionally, ileal biopsies obtained from SpA patients who developed clinically overt Crohn's disease (CD) after treatment with IL-17i (n=5) were analyzed for expression of IL-23/Th-17 related cytokines, IL-25/IL-17E-producing cells and type-2 innate lymphoid cells (ILC2s). RESULTS:There were significant shifts in abundance of specific taxa after treatment with IL-17i compared to TNFi, particularly Clostridiales (p=0.016) and Candida albicans (p=0.041). These subclinical alterations correlated with changes in bacterial community co-occurrence, metabolic pathways, IL-23/Th17-related cytokines and various fatty acids. Ileal biopsies showed that clinically overt CD was associated with expansion of IL-25/IL-17E-producing tuft cells and ILC2s (p<0.05) compared to pre-IL-17i treatment levels. CONCLUSION/CONCLUSIONS:In a subgroup of SpA patients, the initiation of IL-17A blockade correlated with features of subclinical gut inflammation and intestinal dysbiosis of certain bacterial and fungal taxa, most notably C. albicans. Further, IL-17i-related CD was associated with overexpression of IL-25/IL-17E-producing tuft cells and ILC2s. These results may help to explain the potential link between inhibition of a specific IL-17 pathway and the (sub)clinical gut inflammation observed in SpA.
PMID: 31729183
ISSN: 2326-5205
CID: 4185952

Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis Via COX-1 (Cyclooxygenase-2)

Garshick, Michael S; Tawil, Michael; Barrett, Tessa J; Salud-Gnilo, Charissa M; Eppler, Michael; Lee, Angela; Scher, Jose U; Neimann, Andrea L; Jelic, Sanja; Mehta, Nehal N; Fisher, Edward A; Krueger, James G; Berger, Jeffrey S
OBJECTIVE:=0.02). CONCLUSIONS:In patients with psoriasis, platelets are activated and induce endothelial cell inflammation. Low-dose aspirin improved endothelial cell health in psoriasis via platelet COX-1 inhibition. These data demonstrate a previously unappreciated role of platelets in psoriasis and endothelial cell inflammation, which suggests that aspirin may be effective in improving vascular health in patients with psoriasis. Registration: URL: Unique identifier: NCT03228017.
PMID: 32131611
ISSN: 1524-4636
CID: 4339722

Patient health-seeking behavior on WeChat: Social media and dermatology [Case Report]

Tan, Andrea; Gutierrez, Daniel; Milam, Emily C; Neimann, Andrea L; Zampella, John
PMID: 32072002
ISSN: 2352-5126
CID: 4306202

A case of porphyria cutanea tarda in the setting of hepatitis C infection and tobacco usage

Lederhandler, M; Chen, L; Meehan, S A; Brinster, N K; Neimann, A
Porphyria cutanea tarda (PCT) is the most common type of porphyria, presenting in middle-aged patients with a photodistributed vesiculobullous eruption, milia, and scars. Porphyria cutanea tarda occurs in relation to inhibition of uroporphyrinogen decarboxylase, a key enzyme in the heme biosynthesis pathway. A number of genetic and acquired factors increase susceptibility to PCT by reducing uroporphyrinogen decarboxylase activity. A handful of other vesiculobullous conditions may mimic PCT both clinically and histologically; therefore, both skin biopsy and laboratory evaluation are helpful in confirming the diagnosis. We report a case of PCT in the setting of cigarette usage and untreated hepatitis C infection.
PMID: 32045169
ISSN: 1087-2108
CID: 4304302